Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
0.9369
+0.0250 (2.74%)
May 2, 2025, 4:00 PM EDT - Market closed
Ironwood Pharmaceuticals Revenue
In the year 2024, Ironwood Pharmaceuticals had annual revenue of $351.41M, down -20.63%. Ironwood Pharmaceuticals had revenue of $90.55M in the quarter ending December 31, 2024, a decrease of -22.98%.
Revenue (ttm)
$351.41M
Revenue Growth
-20.63%
P/S Ratio
0.42
Revenue / Employee
$1,388,972
Employees
253
Market Cap
150.85M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 351.41M | -91.33M | -20.63% |
Dec 31, 2023 | 442.74M | 32.14M | 7.83% |
Dec 31, 2022 | 410.60M | -3.16M | -0.76% |
Dec 31, 2021 | 413.75M | 24.23M | 6.22% |
Dec 31, 2020 | 389.52M | -38.89M | -9.08% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.19B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
IRWD News
- 3 days ago - Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - Business Wire
- 8 days ago - Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - Business Wire
- 11 days ago - Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support - Business Wire
- 19 days ago - Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug - Benzinga
- 19 days ago - Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide - Business Wire
- 23 days ago - Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth - Seeking Alpha
- 5 weeks ago - Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing - Business Wire
- 5 weeks ago - Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund - Business Wire